Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pilot Study on Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults
Sponsor: ANRS, Emerging Infectious Diseases
Summary
In 1999, when initiating antiretroviral treatment in HIV infected adults, a triple combination with protease inhibitor is recommended. Such therapy induces side effects and the number of pills may reduce therapy adherence. The aim of this study is to evaluate the efficacy and the safety of a once daily FTC, ddI, efavirenz combination, in HIV patients with CD4 cell count over 100/mm3, antiretroviral naive.
Official title: Pilot Study on Efficacy and Safety of a Once Daily FTC, ddI, Efavirenz Combination in Antiretroviral Naive HIV Infected Adults. ANRS 091 MONTANA
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
39
Start Date
1999-02
Completion Date
2004-09
Last Updated
2026-06-15
Healthy Volunteers
No
Conditions
Interventions
emtricitabine, FTC (drug)
didanosine, ddI (drug)
efavirenz (drug)
Locations (1)
Service de Maladies Infectieuses, Hôpital Saint-Louis
Paris, France